These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 24603459)

  • 1. Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth.
    Meng F; DeMorrow S; Venter J; Frampton G; Han Y; Francis H; Standeford H; Avila S; McDaniel K; McMillin M; Afroze S; Guerrier M; Quezada M; Ray D; Kennedy L; Hargrove L; Glaser S; Alpini G
    Am J Physiol Gastrointest Liver Physiol; 2014 May; 306(9):G759-68. PubMed ID: 24603459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma.
    Obchoei S; Weakley SM; Wongkham S; Wongkham C; Sawanyawisuth K; Yao Q; Chen C
    Mol Cancer; 2011 Aug; 10():102. PubMed ID: 21871105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression.
    Fava G; Demorrow S; Gaudio E; Franchitto A; Onori P; Carpino G; Glaser S; Francis H; Coufal M; Marucci L; Alvaro D; Marzioni M; Horst T; Mancinelli R; Benedetti A; Alpini G
    Liver Int; 2009 Aug; 29(7):1031-42. PubMed ID: 19291182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma: its synthesis is reduced favoring cholangiocarcinoma growth.
    Han Y; Demorrow S; Invernizzi P; Jing Q; Glaser S; Renzi A; Meng F; Venter J; Bernuzzi F; White M; Francis H; Lleo A; Marzioni M; Onori P; Alvaro D; Torzilli G; Gaudio E; Alpini G
    Am J Physiol Gastrointest Liver Physiol; 2011 Oct; 301(4):G623-33. PubMed ID: 21778461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth.
    Hall C; Ehrlich L; Venter J; O'Brien A; White T; Zhou T; Dang T; Meng F; Invernizzi P; Bernuzzi F; Alpini G; Lairmore TC; Glaser S
    Cancer Lett; 2017 Feb; 386():179-188. PubMed ID: 27894959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
    J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation.
    Ehrlich L; Hall C; Venter J; Dostal D; Bernuzzi F; Invernizzi P; Meng F; Trzeciakowski JP; Zhou T; Standeford H; Alpini G; Lairmore TC; Glaser S
    Am J Pathol; 2017 Mar; 187(3):570-580. PubMed ID: 28087162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo.
    Francis H; Onori P; Gaudio E; Franchitto A; DeMorrow S; Venter J; Kopriva S; Carpino G; Mancinelli R; White M; Meng F; Vetuschi A; Sferra R; Alpini G
    Mol Cancer Res; 2009 Oct; 7(10):1704-13. PubMed ID: 19825989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis.
    Meng F; Han Y; Staloch D; Francis T; Stokes A; Francis H
    Hepatology; 2011 Nov; 54(5):1718-28. PubMed ID: 21793031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-escin reverses multidrug resistance through inhibition of the GSK3β/β-catenin pathway in cholangiocarcinoma.
    Huang GL; Shen DY; Cai CF; Zhang QY; Ren HY; Chen QX
    World J Gastroenterol; 2015 Jan; 21(4):1148-57. PubMed ID: 25632187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway.
    Fava G; Marucci L; Glaser S; Francis H; De Morrow S; Benedetti A; Alvaro D; Venter J; Meininger C; Patel T; Taffetani S; Marzioni M; Summers R; Reichenbach R; Alpini G
    Cancer Res; 2005 Dec; 65(24):11437-46. PubMed ID: 16357152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma.
    Kosriwong K; Menheniott TR; Giraud AS; Jearanaikoon P; Sripa B; Limpaiboon T
    World J Gastroenterol; 2011 Mar; 17(12):1631-41. PubMed ID: 21472131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression.
    Lu D; Han C; Wu T
    Gastroenterology; 2011 Jun; 140(7):2084-94. PubMed ID: 21354147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocyte nuclear factor 6 inhibits the growth and metastasis of cholangiocarcinoma cells by regulating miR-122.
    Zhu H; Mi Y; Jiang X; Zhou X; Li R; Wei Z; Jiang H; Lu J; Sun X
    J Cancer Res Clin Oncol; 2016 May; 142(5):969-80. PubMed ID: 26825606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurokinin-1 receptor antagonist aprepitant regulates autophagy and apoptosis via ROS/JNK in intrahepatic cholangiocarcinoma.
    Yang Y; Cao X; Wang Y; Wu X; Zhou P; Miao L; Deng X
    Liver Int; 2024 Jul; 44(7):1651-1667. PubMed ID: 38554043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
    Erice O; Labiano I; Arbelaiz A; Santos-Laso A; Munoz-Garrido P; Jimenez-Agüero R; Olaizola P; Caro-Maldonado A; Martín-Martín N; Carracedo A; Lozano E; Marin JJ; O'Rourke CJ; Andersen JB; Llop J; Gómez-Vallejo V; Padro D; Martin A; Marzioni M; Adorini L; Trauner M; Bujanda L; Perugorria MJ; Banales JM
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1335-1344. PubMed ID: 28916388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma.
    Francis H; DeMorrow S; Venter J; Onori P; White M; Gaudio E; Francis T; Greene JF; Tran S; Meininger CJ; Alpini G
    Gut; 2012 May; 61(5):753-64. PubMed ID: 21873469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-494-dependent WDHDI inhibition suppresses epithelial-mesenchymal transition, tumor growth and metastasis in cholangiocarcinoma.
    Liu B; Hu Y; Qin L; Peng XB; Huang YX
    Dig Liver Dis; 2019 Mar; 51(3):397-411. PubMed ID: 30314946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100A8 facilitates cholangiocarcinoma metastasis via upregulation of VEGF through TLR4/NF‑κB pathway activation.
    Pan S; Hu Y; Hu M; Xu Y; Chen M; Du C; Cui J; Zheng P; Lai J; Zhang Y; Bai J; Jiang P; Zhu J; He Y; Wang J
    Int J Oncol; 2020 Jan; 56(1):101-112. PubMed ID: 31746424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF-kappaB and induction of apoptosis.
    Onori P; DeMorrow S; Gaudio E; Franchitto A; Mancinelli R; Venter J; Kopriva S; Ueno Y; Alvaro D; Savage J; Alpini G; Francis H
    Int J Cancer; 2009 Aug; 125(3):565-76. PubMed ID: 19358267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.